LGALS3 and obesity disorder: Previous studies of our group have demonstrated that Gal-3 pharmacological inhibition with MCP prevented cardiac dysfunction, fibrosis and inflammation in several pathophysiological conditions such as hyperaldosteronism5,8, obesity, hypertension6 or aortic stenosis.